|本期目录/Table of Contents|

[1]章磊,流小舟,孙畅综述,等.多途径靶向给药系统在骨肉瘤治疗中的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2016,18(06):632-635.[doi:10.3969/j.issn.1672-271X.2016.06.020]
点击复制

多途径靶向给药系统在骨肉瘤治疗中的研究进展()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第18卷
期数:
2016年06期
页码:
632-635
栏目:
综述
出版日期:
2016-11-20

文章信息/Info

Title:
-
作者:
章磊; 流小舟; 孙畅综述;  黎承军审校
210002江苏南京，南京大学医学院附属金陵医院（南京军区南京总医院）骨科
Author(s):
-
关键词:
骨肉瘤; 靶向给药系统; 骨诱导剂; 纳米载体; 小分子RNA
Keywords:
-
分类号:
R738.1
DOI:
10.3969/j.issn.1672-271X.2016.06.020
文献标志码:
A
摘要:
骨肉瘤是好发于儿童及青少年的恶性骨肿瘤，由于骨组织硬度大、渗透性差和生理生化过程的特殊性，抗肿瘤药物在骨组织很难达到有效的药物浓度。选择增加药物剂量不仅提高了药物毒副反应的发生率，也给患者在治疗过程中带来心理及经济上的压力。实验研究发现了多种途径能使抗肿瘤药物通过自我导向或在外界环境诱导下选择性地与肿瘤组织结合，其中包括通过骨诱导剂（双膦酸盐类）偶联化疗药物、纳米药物载体封装化疗药物以及小分子核糖核酸结合化疗药物等方式。本文就目前国内外研究抗肿瘤药物通过靶向给药系统治疗骨肉瘤的实验成果、理论机制及治疗方向作综述。
Abstract:
-

参考文献/References:

[1]章磊,流小舟,吴苏稼,等.外泌体在骨肉瘤发病机制中的研究进展[J].医学研究生学报,2016,29(2):196-200.
[2]施鑫.骨肉瘤诊断和治疗的现状及进展[J].医学研究生学报,2012,25(5):449-452.
[3]黎承军, 流小舟, 赵建宁, 等. Survivin 基因与骨肉瘤关系的研究进展[J]. 东南国防医药, 2013, 15(3): 276-278.
[4]O′Kane GM, Cadoo KA, Walsh EM, et al. Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review[J]. Clin Sarcoma Res, 2015, 5: 17. doi: 10.1186/s13569-015-0032-0
[5]Tavano L, Muzzalupo R. Multi-functional vesicles for cancer therapy: The ultimate magic bullet[J]. Colloids Surf B Biointerfaces, 2016, 147: 161-171.
[6]Minisola S, Cipriani C, Scillitani A, et al. More on the use of bisphosphonates in the prevention and treatment of osteoporosis [J]. BMJ, 2015, 351:h5868.
[7]Price AP, Abramson SJ, Hwang S, et al. Skeletal imaging effects of pamidronate therapy in osteosarcoma patients[J]. Pediatr Radiol, 2011, 41(4): 451-458.
[8]Ribatti D, Nico B, Mangieri D, et al. Neridronate inhibits angiogenesis in vitro and in vivo[J]. Clin Rheumatol, 2007, 26(7): 1094-1098.
[9]Goldsby RE, Fan TM, Villaluna D, et al. Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group[J]. Eur J Cancer, 2013, 49(10): 2384-2391.
[10]Kozicki AR, Robat C, Chun R, et al. Adjuvant therapy with carboplatin and pamidronate for canine appendicular osteosarcoma[J]. Vet Comp Oncol, 2015, 13(3): 229-236.
[11]Ohba T, Cates JM, Cole HA, et al. Pleiotropic effects of bisphosphonates on osteosarcoma[J]. Bone, 2014, 63(6):110-120.
[12]Meyers PA, Healey JH, Chou AJ, et al. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma[J]. Cancer, 2011, 117(8): 1736-1744.
[13]Erez R, Ebner S, Attali B, et al. Chemotherapeutic bone-targeted bisphosphonate prodrugs with hydrolytic mode of activation[J]. Bioorg Med Chem Lett, 2008, 18(2): 816-820.
[14]Yang XN,Zeng JC,Song YC,et al. Targeted Antiosteosarcoma Methotrexate-bisphosphonate Conjugate induces apoptosis of osteosarcoma cells in vitro[J]. Eur Rev Med Pharmaco, 2014, 18(15): 2116-2123.
[15]Morton SW, Shah NJ, Quadir MA, et al. Osteotropic therapy via targeted layer-by-layer nanoparticles[J]. Adv Health Mater, 2014, 3(6): 867-875.
[16]Wu D, Wan M. Methylene diphosphonate-conjugated adriamycin liposomes: preparation, characteristics, and targeted therapy for osteosarcomas in vitro and in vivo[J]. Biomed Microdevices, 2012, 14(3): 497-510.
[17]Saisyo A, Nakamura H, Fang J, et al. pH-sensitive polymeric cisplatin-ion complex with styrene-maleic acid copolymer exhibits tumor-selective drug delivery and antitumor activity as a result of the enhanced permeability and retention effect [J]. Colloids Surf B Biointerfaces, 2016, 138: 128-137.
[18]Babu A, Amreddy N, Ramesh R. Nanoparticle-based cisplatin therapy for cancer[J]. Ther Deliv, 2015, 6(2): 115-119.
[19]Masaka T, Li Y, Kawatobi S, et al. Liposome modified with VIP-lipopeptide as a new drug delivery system[J]. Yakugaku Zasshi, 2014, 134(9): 987-995.
[20]Sun L, Zhou DS, Zhang P, et al. Gemcitabine and γ-cyclodextrin/docetaxel inclusion complex-loaded liposome for highly effective combinational therapy of osteosarcoma[J]. Int J Pharm, 2015, 478(1): 308-317.
[21]李忱. 负载阿霉素的聚乙二醇-聚亮氨酸胶束在骨肉瘤治疗中的应用[D]. 吉林大学, 2014.
[22]Low SA, Yang JY, Kopecek J. Bone-targeted acid-sensitive doxorubicin conjugate micelles as potential osteosarcoma therapeutics[J]. Bioconjug Chem, 2014, 25(11): 2012-2020.
[23]Chen B, Yang JZ, Wang LF, et al. Ifosfamide-loaded poly (lactic-co-glycolic acid) PLGA-dextran polymeric nanoparticles to improve the antitumor efficacy in osteosarcoma[J]. BMC Cancer，2015，15: 752.doi: 10.1186/s12885-015-1735-6.
[24]郑亦静, 张小磊, 林焱, 等. 双抗体靶向阿霉素纳米药物的研制及其靶向抗骨肉瘤作用[J]. 温州医学院学报, 2015, 45(8): 547-551.
[25]王栋峰, 蔡林, 胡治平, 等. 磁性阿霉素聚氰基丙烯酸正丁酯纳米粒的合成及其对 MG-63 人骨肉瘤细胞的效应[J]. 武汉大学学报(医学版), 2008, 29(5): 610-616.
[26]Shido Y, Nishida Y, Suzuki Y, et al. Targeted hyperthermia using magnetite cationic liposomes and an alternating magnetic field in a mouse osteosarcoma model[J]. J Bone Joint Surg Br, 2010, 92(4): 580-585.
[27]Gonalves M, Figueira P, Maciel D, et al. pH-sensitive Laponite/doxorubicin/alginate nanohybrids with improved anticancer efficacy[J]. Acta Biomater, 2014, 10(1): 300-307.
[28]Haussecker D. The business of RNAi therapeutics in 2012[J]. Mol Ther Nucleic acids, 2012, 1(2): e8.doi: 10.1038/mtna.2011.9.
[29]Rousseau J, Escriou V, Perrot P, et al. Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models[J]. Cancer Gene Ther, 2010, 17(6): 387-397.
[30]Rousseau J, Escriou V, Lamoureux F, et al. Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models[J]. J Bone Miner Res, 2011, 26(10): 2452-2462.
[31]Zhao Y, Tu MJ, Yu YF, et al. Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth[J]. Biochem Pharmacol, 2015, 98(4): 602-613.

相似文献/References:

[1]黎承军,流小舟 赵建宁,吴苏稼,等.Survivin基因与骨肉瘤关系的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2013,15(03):276.[doi:10.3969/j.issn.1672-271X.2013.03.022]
[2]流小舟综述,黎承军,周光新,等.核转录因子Snail与骨肉瘤关系的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2014,16(01):67.
[3]朱婷婷,赵宇蕾,齐谢敏,等.1例大剂量甲氨蝶呤治疗骨肉瘤的药代动力学监护[J].医学研究与战创伤救治(原医学研究生学报),2015,17(02):119.[doi:10.3969/j.issn.1672-271X.2015.02.003]
　ZHU Ting-ting,ZHAO Yu-lei,QI Xie-min,et al.Pharmacokinetic care of high-dose methotrexate in the treatment of osteosarcoma in 1 case[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(06):119.[doi:10.3969/j.issn.1672-271X.2015.02.003]
[4]雷平纷,王丽红,李霞,等.以人文关怀理念为中心的全程化护理在治疗骨肉瘤患者中的应用[J].医学研究与战创伤救治(原医学研究生学报),2021,23(6):657.[doi:10.3969/j.issn.1672-271X.2021.06.022]

备注/Memo

备注/Memo:
江苏省自然科学基金面上项目（BK20151372）
更新日期/Last Update: 2016-11-20